WO2003105888A1 - Saure insulinzubereitungen mit verbesserter stabilität - Google Patents
Saure insulinzubereitungen mit verbesserter stabilität Download PDFInfo
- Publication number
- WO2003105888A1 WO2003105888A1 PCT/EP2003/005887 EP0305887W WO03105888A1 WO 2003105888 A1 WO2003105888 A1 WO 2003105888A1 EP 0305887 W EP0305887 W EP 0305887W WO 03105888 A1 WO03105888 A1 WO 03105888A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- pharmaceutical formulation
- formulation according
- human insulin
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to a pharmaceutical formulation comprising a polypeptide selected from a group comprising insulin, an insulin metabolite, an insulin analog, an insulin derivative or combinations thereof; a surfactant or combinations of several surfactants; optionally a preservative or combinations of several preservatives; and optionally an isotonizing agent, buffer or other adjuvant or combinations thereof, wherein the pharmaceutical formulation has a pH in the acidic range.
- formulations can be used to treat diabetes, and are particularly suitable for preparations where high stability to thermal and / or physical-mechanical stress is required.
- the invention also relates to parenteral compositions containing such formulations which can be used in diabetes as well as methods for preparing the compositions and improving the stability of insulin preparations.
- Insulin secretion the only currently possible therapy. represents. Those affected are lifelong, usually several times a day, rely on insulin injections. In contrast to type I diabetes, the type II diabetes is not always characterized by a lack of insulin, but in a large number of cases, especially in advanced stages, treatment with insulin, possibly in combination with an oral antidiabetic, is the most favorable form of therapy considered. In healthy individuals, insulin release through the pancreas is strictly coupled to the concentration of blood glucose. Increased blood glucose levels, as they occur after meals, are rapidly compensated by a corresponding increase in insulin secretion. In the fasting state of the sinks
- the replacement of the body's insulin secretion by exogenous, usually subcutaneous administration of insulin generally does not approach the above-described quality of the physiological regulation of blood glucose.
- derailments of blood glucose go up or down, which can be life threatening in their most severe forms.
- increased blood glucose levels without initial symptoms represent a considerable health risk over years.
- the large-scale DCCT study in the USA The Diabetes Control and Complications Trial Research Group (1993) N. Engl. J. Med. 329, 977-986) showed clearly that chronically elevated blood glucose levels are significantly responsible for the development of late diabetic damage.
- Diabetic late damage is microvascular and macrovascular damage, which may manifest as retinopathy, nephropathy, or neuropathy, leading to blindness, renal failure, and loss of extremities, in addition to an increased risk of cardiovascular disease. It can be deduced from this that an improved therapy of diabetes must primarily aim to keep the blood glucose as close as possible to the physiological range. According to the concept of intensified insulin therapy, this should be achieved by injections of fast-acting and slow-acting insulin preparations several times a day. Fast-acting formulations are given at meal times to compensate for the postprandial increase in blood glucose. Slow-acting basal insulins should ensure the basic supply of insulin, especially at night, without leading to hypoglycaemia.
- Insulin is a 51 amino acid polypeptide distributed among 2 amino acid chains: the 21 amino acid A chain and the 30 amino acid B chain. The chains are linked by 2 disulfide bridges. Insulin preparations have been used for diabetes therapy for many years. Not only naturally occurring insulins are used, but more recently also insulin derivatives and analogues.
- Insulin analogs are analogs of naturally occurring insulins, namely human insulin or animal insulins, which are replaced by substitution, at least of a naturally occurring amino acid residue with other amino acids and / or addition / removal of at least one amino acid residue from the corresponding otherwise identical naturally occurring insulin. These may also be amino acids that are not naturally occurring.
- Insulin derivatives are derivatives of naturally occurring insulin or an insulin analog obtained by chemical modification.
- the chemical modification may e.g. in the addition of one or more particular chemical groups to one or more amino acids.
- insulin derivatives and insulin analogues have a slightly altered effect on human insulin.
- Insulin analogues with accelerated onset of action are described in EP 0 214 826, EP 0 375437 and EP 0 678 522.
- EP 0 124 826 relates inter alia. on substitutions of B27 and B28.
- EP 0 678 522 describes insulin analogues which have different amino acids in position B29, preferably proline, but not glutamic acid.
- EP 0 375 437 comprises insulin analogues with lysine or arginine in B28, which may optionally be additionally modified in B3 and / or A21.
- EP 0 419 504 discloses insulin analogues which are protected against chemical modifications in which asparagine in B3 and at least one further amino acid in positions A5, A15, A18 or A21 are altered.
- insulin derivatives and insulin analogues have a slightly altered effect on human insulin.
- insulin analogs are described in which at least one amino acid of positions B1-B6 is replaced by lysine or arginine. Such insulins have a prolonged action according to WO 92/00321.
- the insulin analogues described in EP-A 0 368 187 also have a delayed action.
- the insulin preparations on the market for naturally occurring insulins for insulin substitution differ in the origin of insulin (eg beef, pork, human insulin) as well as the composition, with which the effect profile (onset and duration of action) can be influenced. By combining different insulin preparations, different profiles of action can be achieved and, if possible, adjusted to physiological blood sugar levels. Recombinant DNA technology nowadays enables the production of such modified insulins.
- Insulin glargine Gly (A21) Arg (B31) Arg (B32) human insulin
- Insulin glargine is injected as an acidic, clear solution and precipitates as a stable hexamer associate due to its solubility in the physiological pH range of the subcutaneous tissue.
- Insulin glargine is injected once daily and is distinguished from other long-acting insulins by its low serum profile and the associated reduction in the risk of nocturnal hypoglycemia (Schubert-Zsilavecz et al., 2: 125-130 (2001)).
- insulin glargine which leads to the extended duration of action, is characterized by a clear solution with acidic pH, in contrast to previously described preparations.
- acidic pH insulins show a reduced stability and an increased tendency to aggregate under thermal and physico-mechanical stress, which can be manifested in the form of turbidity and precipitation (particle formation) (Brange et al., J. Ph.Sci 86 : 517-525 (1997)).
- the aggregation tendency may additionally be promoted by hydrophobic surfaces which are in contact with the solution (Sluzky et al., Proc. Natl. Acad. Sci 88: 9377-9381 (1991).) As hydrophobic surfaces, the glass vessels of the preparations, finest silicone oil droplets can act as additional hydrophobic aggregation nuclei in taking the daily dose of insulin via commercial, silconized insulin syringes and speeding up the process.
- WO 01/43762 describes aqueous, parenteral pharmaceutical preparations containing a polypeptide and glycerol, in which the stabilization of the preparation is to be achieved by purifying destabilizing constituents of glycerol.
- WO 00/23098 describes insulin preparations stabilized with polysorbate 20 or poloxamer 188 for pulmonary administration, but does not describe the stabilization in acidic solution against aggregation germs.
- the pharmaceutical preparations contain 60-6000 nmol / ml, preferably 240-3000 nmol / ml of an insulin, an insulin metabolite, an insulin analog or an insulin derivative.
- nonionic surfactants can be used inter alia.
- conventional surfactants are pharmaceutically preferred, such as: partial and fatty acid ester and ethers of polyhydric alcohols such as of glycerol, sorbitol, among others (Span ®, Tween ® 20 and Tween ® 1 in particular, Tween ® 80, Myrj ®, Brij ®), Cremophor ® or poloxamers.
- the surfactants are present in the pharmaceutical composition in a concentration of 5-200 ⁇ g / ml, preferably of 5-120 ⁇ g / ml and more preferably of 20-75 ⁇ g / ml.
- the preparation may further contain preservatives (e.g., phenol, cresol, parabens), isotonizing agents (e.g., mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, glycerol). Buffer substances, salts, acids and alkalis and other excipients. These substances may be present individually or as mixtures.
- preservatives e.g., phenol, cresol, parabens
- isotonizing agents e.g., mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, glycerol.
- Buffer substances, salts, acids and alkalis and other excipients may be present individually or as mixtures.
- Glycerol, dextrose, lactose, sorbitol and mannitol are usually present in the pharmaceutical preparation in a concentration of 100-250 mM, NaCl in a concentration of up to 150 mM.
- Buffer substances e.g. Phosphate, acetate, citrate, arginine, glycylglycine or TRIS (ie 2-amino-2-hydroxymethyl-1,3-propanediol) buffer and corresponding salts are in a concentration of 5-250 mM, preferably 10-100 mM available.
- Other excipients may include salts or arginine.
- the invention therefore relates to a pharmaceutical formulation
- a pharmaceutical formulation comprising a polypeptide selected from a group comprising insulin, an insulin analog, an insulin derivative, an active insulin metabolite or combinations thereof; a surfactant or combinations of several surfactants; optionally a preservative or combinations of several preservatives; and optionally an isotonizing agent, buffering agents and / or other adjuvants or combinations thereof, wherein the pharmaceutical formulation is a clear solution having a pH in the acidic range (pH 1-6.8), preferably pH 3.5-6.8 , most preferably 3.5 - 4.5, has.
- the surfactant is selected from a group containing partial and fatty acid esters and ethers of polyhydric alcohols such as glycerol and sorbitol, polyols; wherein the partial and fatty acid esters and ethers of glycerol and sorbitol are selected from a Group comprising clamping ®, Tween ®, Myrj ®, Brij ®, Cremophor ®; wherein the polyols are selected from the group consisting of polypropylene glycols, polyethylene glycols, poloxamers, Pluronics, Tetronics; wherein the preservative is selected from a group containing phenol, cresol, parabens; wherein the isotonizing agent is selected from a group containing mannitol, sorbitol, sodium chloride, glycerol; wherein the auxiliaries are selected from a group containing buffer substances, acids, alkalis; wherein
- the invention further provides a pharmaceutical formulation as described above, in which the insulin, the insulin analog, the active insulin metabolite and / or the insulin derivative are present in a concentration of 60-6000 nmol / ml, preferably in a concentration of 240-3000 nmol / ml is present (this corresponds approximately to a concentration of 1.4-35 mg / ml or 40-500 units / ml); in which the surfactant is present in a concentration of 5-200 ⁇ g / ml, preferably of 5-120 ⁇ g / ml and more preferably of 20-75 ⁇ g / ml.
- Another object of the invention is a pharmaceutical formulation as stated above, in which glycerol and / or mannitol in a concentration of 100-250 mM, and / or NaCl preferably in a concentration up to 150 mM.
- Another object of the invention is a pharmaceutical formulation as stated above, in which a buffer substance in a concentration of 5 - 250 mM is present.
- Another object of the invention is a pharmaceutical insulin formulation, the further additives such. Contains salts which retard the release of insulin.
- Another object of the invention is a method for producing such pharmaceutical formulations.
- another object of the invention is the use of such formulations for the treatment of diabetes mellitus.
- Another object of the invention is the use or the addition of
- Insulin analogues or insulin derivatives or their preparations are insulin analogues or insulin derivatives or their preparations.
- insulin analogue insulin glargine Gly (A21), Arg (B31), Arg (B32) human insulin.
- insulin glargine is suspended in one part of water for injections, dissolved at pH 3-4, the other ingredients are added, the pH adjusted to 4.0 +/- 0.2 with hydrochloric acid / NaOH and the final volume refilled.
- the concentration of insulin glargine in each of the experiments described below is 3.6378 mg / ml (equivalent to 100 units / ml).
- a second preparation is prepared identically, but still a certain amount of a surfactant is added. The solutions are filled into 10 ml glass vials and crimped. These vessels are now exposed to simulated stress or physical-mechanical stress conditions:
- the haze value corresponds to the intensity of the scattered radiation of the incident light on suspended particles in the sample.
- Example 1 Stabilization of the in Use Period of Insulin glargine with polysorbate 20 (Tween ® 20)
- Example 2 Stabilization of Insulin Glargine with Polysorbate 20 under Physical Mechanical Stress
- the solution is sterile filtered through a combination of 0.2 micron and 0.1 micron filter.
- the samples are stored at +5 ° C, 25 ° C and 37 ° C for a specified period of time. Each 5 samples are then subjected to a shaking test.
- polysorbate 20 Without addition of polysorbate 20, a visible turbidity can already occur in the solution after 2 days of strong physical-mechanical stress.
- the addition of polysorbate 20 can significantly delay haze formation during physical-mechanical stressing.
- the stabilizing effect of Polysorbat 20 remains even when stored at elevated temperatures.
- a decrease in the stabilizing effect by possible hydrolysis of the polysorbate in the acidic medium of the solution can not be determined.
- Example 3 Comparison of stabilization of the in Use Period of Insulin glargine with polysorbate 20 (Tween ® 20) and polysorbate 80 (Tween ® 20) Open 10 vials each to 5 ml insulin glargine injection solution and a) add 0.001 mg / ml polysorbate 20 b) add 0.01 mg / ml polysorbate 20 c) add 0.001 mg / ml polysorbate 80 d) add 0, 01 mg / ml polysorbate 80 in the form of a concentrated stock solution.
- the samples are then subjected to a use test.
- Addition of polysorbate 20 or polysorbate 80 at a concentration of 0.01 mg / ml is equally capable of stabilizing the solution against particle formation during the in-use period.
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200500437A UA79477C2 (en) | 2002-06-18 | 2003-05-06 | Acid insulin compositions with increased stability |
NZ537211A NZ537211A (en) | 2002-06-18 | 2003-06-05 | Acidic insulin preparations with improved stability |
MEP-287/08A MEP28708A (en) | 2002-06-18 | 2003-06-05 | Acidic insulin preparations with improved stability |
CA2490116A CA2490116C (en) | 2002-06-18 | 2003-06-05 | Acidic insulin preparations with improved stability |
EP10178842.0A EP2305288B1 (de) | 2002-06-18 | 2003-06-05 | Saure Insulinzubereitungen mit verbesserter Stabilität |
JP2004512789A JP5237522B2 (ja) | 2002-06-18 | 2003-06-05 | 改善された安定性を有する酸性インスリン調製物 |
YU105704A RS52388B (sr) | 2002-06-18 | 2003-06-05 | Kiseli preparati insulina sa poboljšanom stabilnošću |
AU2003238471A AU2003238471B2 (en) | 2002-06-18 | 2003-06-05 | Acidic insulin preparations with improved stability |
MXPA04012233A MXPA04012233A (es) | 2002-06-18 | 2003-06-05 | Preparaciones acidas de insulina con estabilidad mejorada. |
KR1020047020482A KR101040029B1 (ko) | 2002-06-18 | 2003-06-05 | 안정성이 개선된 산성 인슐린 제제 |
EP03732536A EP1517697B1 (de) | 2002-06-18 | 2003-06-05 | Saure insulinzubereitungen mit verbesserter stabilität |
ES03732536T ES2397158T3 (es) | 2002-06-18 | 2003-06-05 | Preparaciones ácidas de insulina con estabilidad mejorada |
BRPI0311877A BRPI0311877B8 (pt) | 2002-06-18 | 2003-06-05 | formulação farmacêutica ácida de insulina com estabilidade aperfeiçoada |
DK03732536.2T DK1517697T3 (da) | 2002-06-18 | 2003-06-05 | Sure insulinpræparater med forbedret stabilitet |
ZA2004/09273A ZA200409273B (en) | 2002-06-18 | 2004-11-18 | Acidic insulin preparations with improved stability |
IL165788A IL165788A (en) | 2002-06-18 | 2004-12-15 | Acidic insulin preparations with improved resistance |
TNP2004000249A TNSN04249A1 (en) | 2002-06-18 | 2004-12-16 | Acidic insulin preparations with improved stability |
HRP20041200AA HRP20041200B1 (hr) | 2002-06-18 | 2004-12-17 | Kiseli inzulinski pripravci poboljšane postojanosti |
NO20050036A NO328567B1 (no) | 2002-06-18 | 2005-01-04 | Sure insulinpreparater med forbedret stabilitet |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10227232A DE10227232A1 (de) | 2002-06-18 | 2002-06-18 | Saure Insulinzubereitungen mit verbesserter Stabilität |
DE10227232.8 | 2002-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003105888A1 true WO2003105888A1 (de) | 2003-12-24 |
Family
ID=29723248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/005887 WO2003105888A1 (de) | 2002-06-18 | 2003-06-05 | Saure insulinzubereitungen mit verbesserter stabilität |
Country Status (38)
Country | Link |
---|---|
US (4) | US20040048783A1 (de) |
EP (2) | EP1517697B1 (de) |
JP (2) | JP5237522B2 (de) |
KR (1) | KR101040029B1 (de) |
CN (2) | CN1662252A (de) |
AR (1) | AR039688A1 (de) |
AU (1) | AU2003238471B2 (de) |
BR (1) | BRPI0311877B8 (de) |
CA (1) | CA2490116C (de) |
CR (1) | CR7614A (de) |
CY (1) | CY1113537T1 (de) |
DE (1) | DE10227232A1 (de) |
DK (1) | DK1517697T3 (de) |
EC (1) | ECSP045496A (de) |
ES (2) | ES2397158T3 (de) |
HN (1) | HN2003000184A (de) |
HR (1) | HRP20041200B1 (de) |
IL (1) | IL165788A (de) |
MA (1) | MA27205A1 (de) |
ME (1) | MEP28708A (de) |
MX (1) | MXPA04012233A (de) |
MY (1) | MY142354A (de) |
NO (1) | NO328567B1 (de) |
NZ (1) | NZ537211A (de) |
OA (1) | OA12870A (de) |
PA (1) | PA8575701A1 (de) |
PE (1) | PE20040560A1 (de) |
PL (1) | PL208773B1 (de) |
PT (2) | PT2305288T (de) |
RS (1) | RS52388B (de) |
RU (1) | RU2313362C2 (de) |
SV (1) | SV2004001556A (de) |
TN (1) | TNSN04249A1 (de) |
TW (1) | TWI315201B (de) |
UA (1) | UA79477C2 (de) |
UY (1) | UY27854A1 (de) |
WO (1) | WO2003105888A1 (de) |
ZA (1) | ZA200409273B (de) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007135117A2 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations |
WO2008006496A1 (de) * | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes insulin glargin |
WO2010028055A1 (en) * | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
US8410048B2 (en) | 2006-07-11 | 2013-04-02 | Sanofi-Aventis Deutschland Gmbh | Method for producing insulin analogs having a dibasic B chain terminus |
US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
US9345750B2 (en) | 2010-05-19 | 2016-05-24 | Sanofi | Long-acting formulations of insulin |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
US9644017B2 (en) | 2008-01-09 | 2017-05-09 | Sanofi-Aventis Deutschland Gmbh | Insulin derivatives having an extremely delayed time-action profile |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US10092513B2 (en) | 2013-04-03 | 2018-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US11278624B2 (en) | 2016-05-06 | 2022-03-22 | Arecor Limited | Formulations |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
US7279457B2 (en) * | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
EP1758540A4 (de) * | 2004-05-24 | 2007-06-20 | Wockhardt Ltd | Reinigung von insulinartigem material durch umkehrphasen-chromatographie |
UA75030C2 (en) * | 2005-11-30 | 2006-03-15 | Viktor Oleksandrovych Bykov | Method for obtaining stable aqueous solutions of drugs |
JP2010525033A (ja) * | 2007-04-30 | 2010-07-22 | ノボ・ノルデイスク・エー/エス | 高濃縮のインスリン溶液及び組成物 |
CN101951957A (zh) * | 2008-01-04 | 2011-01-19 | 百达尔公司 | 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂 |
JP5695909B2 (ja) | 2008-01-09 | 2015-04-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
US8951973B2 (en) * | 2008-08-29 | 2015-02-10 | Kevin Burton | Controlled-released peptide formulations |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
RU2540485C2 (ru) * | 2009-07-06 | 2015-02-10 | Санофи-Авентис Дойчланд Гмбх | Препарат инсулина, содержащий метионин |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
WO2011156476A2 (en) * | 2010-06-08 | 2011-12-15 | Biodel Inc. | Insulin with a basal release profile |
CN102188367B (zh) * | 2011-01-05 | 2012-11-07 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
AU2012208349A1 (en) | 2011-01-20 | 2013-07-18 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
MX2014001190A (es) * | 2011-08-10 | 2014-05-12 | Adocia | Solucion inyectable de al menos insulina basal. |
US10350139B2 (en) | 2011-10-25 | 2019-07-16 | Corning Incorporated | Pharmaceutical glass packaging assuring pharmaceutical sterility |
EP2771298B1 (de) | 2011-10-25 | 2017-12-13 | Corning Incorporated | Pharmazeutische delaminationsresistente glasbehälter mit pharmazeutischen wirkstoffen |
BR112014016889A8 (pt) | 2012-01-09 | 2017-07-04 | Adocia | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
CN107952065A (zh) | 2012-11-13 | 2018-04-24 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
US9707275B2 (en) * | 2012-12-19 | 2017-07-18 | Wockhardt Limited | Stable aqueous composition comprising human insulin or an analogue or derivative thereof |
WO2014102623A1 (en) | 2012-12-26 | 2014-07-03 | Wockhardt Limited | Pharmaceutical composition |
TWI641381B (zh) * | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
JP7173953B2 (ja) * | 2014-01-09 | 2022-11-16 | サノフイ | インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤 |
BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
CA2932875A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
MY186251A (en) | 2014-01-20 | 2021-06-30 | Hanmi Pharm Ind Co Ltd | Long-acting insulin and use thereof |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
CN107108711B (zh) * | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
TW201630622A (zh) | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
WO2017179615A1 (ja) * | 2016-04-15 | 2017-10-19 | 富士フイルム株式会社 | マイクロニードルアレイ及びマイクロニードルアレイの製造方法 |
KR20180033105A (ko) | 2016-09-23 | 2018-04-02 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
JP2020511513A (ja) | 2017-03-23 | 2020-04-16 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途 |
BR112019022212A2 (pt) | 2017-06-01 | 2020-05-12 | Eli Lilly And Company | Composições de insulina de ação rápida |
JP2022534926A (ja) * | 2019-05-29 | 2022-08-04 | サノフイ | 薬物送達デバイス |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2456522A1 (fr) | 1979-05-18 | 1980-12-12 | Kao Corp | Composition d'insuline, son procede de preparation et son application en therapeutique |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
WO1992000321A1 (en) * | 1990-06-28 | 1992-01-09 | Novo Nordisk A/S | Novel, protracted insulin analogues |
DE4140186A1 (de) | 1991-12-05 | 1993-06-09 | Alfatec-Pharma Gmbh, 6900 Heidelberg, De | Perorale applikationsform fuer peptidarzneistoffe, insbesondere insulin |
WO2000023098A1 (en) | 1998-10-16 | 2000-04-27 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
WO2001043762A2 (en) | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | Polypeptide compositions with improved stability |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
US3758683A (en) | 1971-04-30 | 1973-09-11 | R Jackson | Insulin product |
GB1554157A (en) * | 1975-06-13 | 1979-10-17 | Takeda Chemical Industries Ltd | Stable insulin preparation for intra nasal administration |
US4153689A (en) * | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
GB1527605A (en) * | 1975-08-20 | 1978-10-04 | Takeda Chemical Industries Ltd | Insulin preparation for intranasal administration |
JPS52156913A (en) * | 1976-06-21 | 1977-12-27 | Toko Yakuhin Kogyo Kk | Production of injectionable medicine |
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
DE3033127A1 (de) | 1980-09-03 | 1982-04-08 | Hoechst Ag, 6000 Frankfurt | Neue analoga des insulins |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
AU558474B2 (en) | 1981-07-17 | 1987-01-29 | Nordisk Insulinlaboratorium | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
NL193099C (nl) | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
DE3316363A1 (de) | 1983-05-05 | 1984-11-08 | Deutsche Babcock Anlagen Ag, 4200 Oberhausen | Walzenrost fuer muellverbrennungsanlagen |
DE3326473A1 (de) * | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
DE3326472A1 (de) * | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
US5177068A (en) * | 1984-04-19 | 1993-01-05 | National Research Development Corporation | Pharmaceutical compositions |
US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
CA1244347A (en) | 1984-05-29 | 1988-11-08 | Eddie H. Massey | Stabilized insulin formulations |
ATE50502T1 (de) * | 1984-06-09 | 1990-03-15 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
DE3440988A1 (de) | 1984-11-09 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung |
DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
CA1274774A (en) | 1985-04-15 | 1990-10-02 | Kenneth S. Su | Method for administering insulin |
DE3526995A1 (de) | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
US5496924A (en) * | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
DE3541856A1 (de) | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
CA1275922C (en) | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
DE3544295A1 (de) * | 1985-12-14 | 1987-06-19 | Bayer Ag | Thermoplastische formmassen mit hoher kriechstromfestigkeit |
NZ223630A (en) | 1987-02-25 | 1989-11-28 | Novo Industri As | Insulin derivative and pharmaceutical compositions |
US5034415A (en) * | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
DE3726655A1 (de) * | 1987-08-11 | 1989-02-23 | Hoechst Ag | Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US5210038A (en) * | 1988-12-22 | 1993-05-11 | Becton, Dickinson And Company | Multiplate subculture solid media devices |
WO1990007522A1 (en) | 1988-12-23 | 1990-07-12 | Novo Nordisk A/S | Human insulin analogues |
PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US4886164A (en) * | 1989-06-16 | 1989-12-12 | Enviro Med, Inc. | Containers for medical waste |
US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
EP0532546B1 (de) * | 1990-05-10 | 1998-03-18 | Bechgaard International Research And Development A/S | Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole |
DK10191D0 (da) * | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
US5614219A (en) * | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
US6468959B1 (en) * | 1991-12-05 | 2002-10-22 | Alfatec-Pharm Gmbh | Peroral dosage form for peptide containing medicaments, in particular insulin |
EP0600372B1 (de) | 1992-12-02 | 1997-02-05 | Hoechst Aktiengesellschaft | Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken |
BR9307687A (pt) | 1992-12-18 | 2002-02-19 | Lilly Co Eli | Análogos de insulina |
JP2743761B2 (ja) * | 1993-03-19 | 1998-04-22 | 松下電器産業株式会社 | 走査型プローブ顕微鏡および原子種同定方法 |
US5514656A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy |
US5882944A (en) | 1993-06-23 | 1999-03-16 | The Regents Of The University Of California | Methods for G protein coupled receptor activity screening |
US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
EP0637073A1 (de) * | 1993-07-29 | 1995-02-01 | STMicroelectronics S.r.l. | Verfahren zur herstellung von P-Kanal MOS-Transistoren für komplementäre Bauteille (CMOS) |
US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
DE4405179A1 (de) * | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
DE4406467A1 (de) * | 1994-02-23 | 1995-08-24 | Dragoco Gerberding Co Ag | Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung |
US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5559094A (en) * | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
EP1002529A1 (de) | 1994-09-09 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Zubereitung mit verzögerter Freigabe eines Metallsalz eines Peptids |
US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US5496164A (en) * | 1994-10-20 | 1996-03-05 | The Conair Group, Inc. | In-line tubing die |
US5824638A (en) * | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
EP0831922A2 (de) | 1995-06-08 | 1998-04-01 | Therexsys Limited | Verwendung virus-ähnlicher partikel in der gentherapie |
CA2224381A1 (en) * | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE19545257A1 (de) * | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5948751A (en) * | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
US5656772A (en) * | 1996-07-19 | 1997-08-12 | Markel; Philip A. | Gas pressure gauge clamp |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US6310038B1 (en) * | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
DE69834028T2 (de) | 1997-03-20 | 2006-12-07 | Novo Nordisk A/S | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
US6043214A (en) * | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
ZA984697B (en) * | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
WO1999034821A1 (en) * | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
US6489292B1 (en) * | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
DE19908041A1 (de) * | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
AU2001220765A1 (en) * | 2000-01-24 | 2001-07-31 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
US6267481B1 (en) * | 2000-04-05 | 2001-07-31 | Jeng Tai Umbrella Mfg., Corp. | Illumination assembly for an umbrella |
DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
US6960551B2 (en) * | 2002-08-23 | 2005-11-01 | Exxonmobil Research And Engineering Company | Functionalized periodic mesoporous materials, their synthesis and use |
US6906897B1 (en) * | 2003-02-28 | 2005-06-14 | Western Digital Technologies, Inc. | Disk drive including an actuator main coil and an actuator secondary coil with a lateral segment and method of operating same |
-
2002
- 2002-06-18 DE DE10227232A patent/DE10227232A1/de not_active Ceased
-
2003
- 2003-05-06 UA UAA200500437A patent/UA79477C2/uk unknown
- 2003-06-05 EP EP03732536A patent/EP1517697B1/de not_active Expired - Lifetime
- 2003-06-05 JP JP2004512789A patent/JP5237522B2/ja not_active Expired - Lifetime
- 2003-06-05 CA CA2490116A patent/CA2490116C/en not_active Expired - Lifetime
- 2003-06-05 RS YU105704A patent/RS52388B/sr unknown
- 2003-06-05 AU AU2003238471A patent/AU2003238471B2/en not_active Expired
- 2003-06-05 ES ES03732536T patent/ES2397158T3/es not_active Expired - Lifetime
- 2003-06-05 BR BRPI0311877A patent/BRPI0311877B8/pt active IP Right Grant
- 2003-06-05 PT PT101788420T patent/PT2305288T/pt unknown
- 2003-06-05 RU RU2005100959/15A patent/RU2313362C2/ru not_active IP Right Cessation
- 2003-06-05 KR KR1020047020482A patent/KR101040029B1/ko active IP Right Grant
- 2003-06-05 NZ NZ537211A patent/NZ537211A/en not_active IP Right Cessation
- 2003-06-05 EP EP10178842.0A patent/EP2305288B1/de not_active Expired - Lifetime
- 2003-06-05 WO PCT/EP2003/005887 patent/WO2003105888A1/de active Application Filing
- 2003-06-05 OA OA1200400332A patent/OA12870A/en unknown
- 2003-06-05 CN CN038138107A patent/CN1662252A/zh active Pending
- 2003-06-05 CN CN201110056210.9A patent/CN102133393B/zh not_active Expired - Lifetime
- 2003-06-05 ME MEP-287/08A patent/MEP28708A/xx unknown
- 2003-06-05 ES ES10178842T patent/ES2817879T3/es not_active Expired - Lifetime
- 2003-06-05 PT PT37325362T patent/PT1517697E/pt unknown
- 2003-06-05 PL PL372072A patent/PL208773B1/pl unknown
- 2003-06-05 MX MXPA04012233A patent/MXPA04012233A/es active IP Right Grant
- 2003-06-05 DK DK03732536.2T patent/DK1517697T3/da active
- 2003-06-11 PE PE2003000581A patent/PE20040560A1/es not_active Application Discontinuation
- 2003-06-13 US US10/461,740 patent/US20040048783A1/en not_active Abandoned
- 2003-06-13 PA PA20038575701A patent/PA8575701A1/es unknown
- 2003-06-16 SV SV2003001556A patent/SV2004001556A/es not_active Application Discontinuation
- 2003-06-16 UY UY27854A patent/UY27854A1/es not_active IP Right Cessation
- 2003-06-16 TW TW092116208A patent/TWI315201B/zh not_active IP Right Cessation
- 2003-06-17 HN HN2003000184A patent/HN2003000184A/es unknown
- 2003-06-17 AR ARP030102141A patent/AR039688A1/es not_active Application Discontinuation
- 2003-06-17 MY MYPI20032252A patent/MY142354A/en unknown
-
2004
- 2004-11-16 MA MA27953A patent/MA27205A1/fr unknown
- 2004-11-18 ZA ZA2004/09273A patent/ZA200409273B/en unknown
- 2004-12-08 CR CR7614A patent/CR7614A/es unknown
- 2004-12-15 IL IL165788A patent/IL165788A/en active IP Right Grant
- 2004-12-15 EC EC2004005496A patent/ECSP045496A/es unknown
- 2004-12-16 TN TNP2004000249A patent/TNSN04249A1/en unknown
- 2004-12-17 HR HRP20041200AA patent/HRP20041200B1/hr not_active IP Right Cessation
-
2005
- 2005-01-04 NO NO20050036A patent/NO328567B1/no not_active IP Right Cessation
- 2005-03-25 US US11/089,777 patent/US7476652B2/en not_active Expired - Lifetime
-
2008
- 2008-12-04 US US12/328,208 patent/US7713930B2/en not_active Expired - Lifetime
-
2010
- 2010-05-04 US US12/773,356 patent/US20100216692A1/en not_active Abandoned
- 2010-10-15 JP JP2010232142A patent/JP2011006492A/ja active Pending
-
2013
- 2013-01-09 CY CY20131100021T patent/CY1113537T1/el unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2456522A1 (fr) | 1979-05-18 | 1980-12-12 | Kao Corp | Composition d'insuline, son procede de preparation et son application en therapeutique |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
WO1992000321A1 (en) * | 1990-06-28 | 1992-01-09 | Novo Nordisk A/S | Novel, protracted insulin analogues |
DE4140186A1 (de) | 1991-12-05 | 1993-06-09 | Alfatec-Pharma Gmbh, 6900 Heidelberg, De | Perorale applikationsform fuer peptidarzneistoffe, insbesondere insulin |
WO2000023098A1 (en) | 1998-10-16 | 2000-04-27 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
WO2001043762A2 (en) | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | Polypeptide compositions with improved stability |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007135117A3 (en) * | 2006-05-24 | 2008-03-20 | Novo Nordisk As | Soluble, stable insulin-containing formulations |
WO2007135117A2 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations |
WO2008006496A1 (de) * | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes insulin glargin |
US8048854B2 (en) | 2006-07-11 | 2011-11-01 | Sanofi-Aventis Deutschland Gmbh | Amidated insulin glargine |
US8410048B2 (en) | 2006-07-11 | 2013-04-02 | Sanofi-Aventis Deutschland Gmbh | Method for producing insulin analogs having a dibasic B chain terminus |
US9644017B2 (en) | 2008-01-09 | 2017-05-09 | Sanofi-Aventis Deutschland Gmbh | Insulin derivatives having an extremely delayed time-action profile |
WO2010028055A1 (en) * | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
US10117909B2 (en) | 2008-10-17 | 2018-11-06 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1 agonist |
US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
US10028910B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
US9345750B2 (en) | 2010-05-19 | 2016-05-24 | Sanofi | Long-acting formulations of insulin |
US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US9745360B2 (en) | 2012-12-21 | 2017-08-29 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists |
US10253079B2 (en) | 2012-12-21 | 2019-04-09 | Sanofi | Functionalized Exendin-4 derivatives |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US11191722B2 (en) | 2013-04-03 | 2021-12-07 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10092513B2 (en) | 2013-04-03 | 2018-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
US11278624B2 (en) | 2016-05-06 | 2022-03-22 | Arecor Limited | Formulations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1517697B1 (de) | Saure insulinzubereitungen mit verbesserter stabilität | |
EP2289539B1 (de) | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität | |
EP2451437B1 (de) | Wässrige insulinzubereitungen enthaltend methionin | |
EP3417871B1 (de) | Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin | |
EP2498801B1 (de) | HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN | |
EP2349324B1 (de) | Kombination von einem insulin und einem glp-1-agonisten | |
DE69329651T3 (de) | Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält | |
EP2451471A1 (de) | Langsamwirkende insulinzubereitungen | |
EP2451472A1 (de) | Hitze- und schüttelstabile insulinzubereitungen | |
DE102008053048A1 (de) | Kombination von einem Insulin und einem GLP-1-Agonisten | |
EP1723172B1 (de) | Erythropoietin-flüssigformulierung | |
DE102008051834A1 (de) | Kombination von einem Insulin und einem GLP-1-Agonisten | |
DE102009038210A1 (de) | Kombination von einem Insulin und einem GLP-1-Agonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-1057/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004/09273 Country of ref document: ZA Ref document number: 200409273 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-501933 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2004000337 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003732536 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/012233 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2807/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537211 Country of ref document: NZ Ref document number: 20038138107 Country of ref document: CN Ref document number: 2003238471 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2490116 Country of ref document: CA Ref document number: 2004512789 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047020482 Country of ref document: KR Ref document number: 372072 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20041200A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500062 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2005100959 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047020482 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003732536 Country of ref document: EP |